Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

ive translation adjustment(190)(150)Total stockholders' deficit(16,073)(52,173)Total liabilities, redeemable common stock and stockholders' deficit$

7,570$

212 

 NORTHWEST BIOTHERAPEUTICS, INC.(A Development Stage Company)CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)Years Ended December 31,Period from
Inception (March 18,
1996) to20122011December 31, 2012Revenues:Research material sales$

-$

10$

580Contract research and development from related parties--1,128Research grants and other772-1,833Total revenues772103,541Operating cost and expenses:Cost of research material sales--382Research and development28,90813,452119,172General and administration15,67513,33590,999Depreciation and amortization14102,377Loss on facility sublease--895Asset impairment loss--2,445Total operating costs and expenses44,59726,797216,270Loss from operations(43,825)(26,787)(212,729)Other income (expense):Valuation of reclassified equity instruments4918,82116,071Conversion inducement expense(9,103)(7,944)(27,337) Accretion of redeemable securities(2,042)-(2,042)Derivative valuation gain/(loss)6017281,383Gain on sale of intellectual property and property and equipment--3,664Interest expense(13,442)(7,648)(55,006)Interest income and other--1,707Net loss(67,320)(32,830)(274,289)Issuance of common stock in connection with elimination of Series A and Series A-1  preferred stock preferences--(12,349)Modification of Series A preferred stock warrants--(2,306)Modification of Series A-1 preferred stock warrants--(16,393)Series A preferred stock dividends--(334)Series A-1 preferred stock dividends--(917)Warrants issued on Series A and Series A-1 preferred stock dividends--(4,664)Accretion of Series A preferred stock mandatory redemption obligation--(1,872)Series A preferred stock redemption fee--(1,700)Beneficial conversion feature of Series D preferred stock--(4,274)Net loss applicable to common stock
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
10. Palatin Technologies To Present At The 25th Annual ROTH Conference
11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.502 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
... Plasmid , Mini Kit , ... James Griffith and Kim Vollmer , James Griffith, ... Instruments, Biosytems Application Lab, Westbury, , NY , , ... , Cosmids are commonly used vectors in the lab, providing the ...
... , , , , Other important parameters for optimizing electroporation., , , , ... , , Pulse length , ... field pulses , Adjustment , of ... , Influence , of temperature , ...
Cached Biology Technology:Agrobacterium tumefaciens 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 3Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 4Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 5
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... SALT LAKE CITY A single organ may contain more ... that complicates prospects for using the versatile cells to replace ... new study from the laboratory of geneticist Mario Capecchi, the ... online issue of the journal Nature Genetics, Capecchi and geneticist ...
... challenges is to understand the design principles and origins ... on the evolutionary origins of the brain and how ... humans. The research suggests that it is not ... during evolution, increasingly sophisticated molecular processing of nerve impulses ...
... Communication,Intelligence Corporation (the "Company") (OTC Bulletin Board: ... business process,automation in the financial industry and the ... it has closed a financing, on,June 5, 2008, ... As part of the financing, the Company ...
Cached Biology News:Caution on stem cell therapy 2Caution on stem cell therapy 3Caution on stem cell therapy 4Origins of the brain 2Origins of the brain 3Communication Intelligence Corporation Closes $3.6 Million Financing 2Communication Intelligence Corporation Closes $3.6 Million Financing 3Communication Intelligence Corporation Closes $3.6 Million Financing 4
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: